SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer

The goal of this phase 2 study is to learn about the efficacy and safety of short-course radiotherapy (SCRT) sequential Penpulimab in combination with CAPEOX in the neoadjuvant treatment of microsatellite stable (MSS) locally advanced rectal cancer. The main question it aims to answer is the role of immune checkpoint inhibitors in the neoadjuvant treatment of MSS rectal cancer. Participants will receive neoadjuvant treatment of SCRT sequential Penpulimab in combination with CAPEOX. Participants will undergo a clinical re-staging assessment at the end of neoadjuvant therapy to determine whether

Trial Details

NCT ID

NCT05576480

Phase

PHASE2

Sponsor

Ruijin Hospital

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

• Short-course radiotherapy
• Penpulimab
• CAPEOX
• TME surgery

Locations (sample)

• Shanghai, None Selected, China|31.22222,121.45806

Key Eligibility Criteria

• Informed consent
• 18 years \< age ≤ 75 years
• ECOG score is 0-1
• Patients with pathologically confirmed rectal adenocarcinoma, assessed by MRI as mid-low rectal cancer (the lower border of the tumor is less than …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →